Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
January 13 2022 - 6:05AM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on sickle cell
disease, prostate cancer and other rare hematologic diseases and
cancers, today announced that Arturo Molina, M.D., M.S., F.A.C.P.,
has been elected to serve on the company’s board of directors and
R&D committee.
Dr. Molina is an internationally acclaimed clinician, hematology
and oncology researcher, practicing physician and pioneer for
change in healthcare inequities. He has over 25 years experience in
biopharma, hematology and oncology and currently serves as chief
medical officer at Sutro Biopharma, where he is responsible for the
clinical development of oncology and hematology therapeutics. Prior
to Sutro, Dr. Molina served as Vice President of Oncology
Scientific Innovation at Johnson & Johnson’s California
Innovation Center and Chief Medical Officer and Vice President of
Clinical Development for Johnson and Johnson’s Ortho Biotech
Oncology Research and Development, Chief Medical Officer at Cougar
Biotechnology which was acquired by Johnson and Johnson and Senior
Director and Interim Head of Oncology/Hematology in the Department
of Medical Research and Clinical Development at Biogen Idec,
Inc.
“I am excited to welcome Arturo at this pivotal stage of growth
for Forma,” said Peter Wirth, chair of Forma’s board of directors.
“Arturo’s exceptional clinical and administrative acumen in the
fields of hematology and oncology will inform Forma’s work as it
continues advancing treatments to meet the needs of these important
patient populations.”
Additionally, Dr. Molina is a member of the American Society of
Hematology’s Committee on Promoting Diversity and the National
Advisory Committee of the Amos Medical Faculty Development Program,
a Robert Wood Johnson Foundation program focused on increasing the
number of medical, dental and nursing faculty from historically
disadvantaged backgrounds. Dr. Molina is also an adjunct clinical
associate professor at the Stanford School of Medicine, Oncology
Division.
“We are thrilled Arturo is joining us at Forma. His global
clinical, drug development and launch experience will be vital to
Forma as we continue to develop therapies with the goal of
transforming patients’ lives around the world,” said Frank Lee,
president and chief executive officer of Forma. “Arturo’s
operational and strategic experience in pioneering new solutions
will help us to deliver on our mission in very concrete ways as we
work to ensure our therapies are successful in the clinic and
ultimately reach patients in need.”
“I am honored to join the board and R&D Committee of Forma,
whose unequivocal patient-focused and culturally aware approach to
challenging diseases aligns with my work,” said Dr. Molina. “I’m
eager to share my clinical drug development and research expertise
to advance Forma’s exciting pipeline and patient-focused
mission.”
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements and
information within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
express or implied statements regarding the advancement of our
clinical programs, our expectations of the therapeutic benefits
related thereto, and our growth as a company and the anticipated
contributions of the members of our board of directors to our
operations and progress. The use of words such as “may,” “will,”
“could,” “would,” “should,” “expects,” “intends,” “plans,”
“anticipates,” “believes,” “estimates,” “ensure”, “predicts,”
“projects,” “seeks,” “endeavors,” “potential,” “continue,” “target”
or the negative of such words or other similar expressions can be
used to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any express or implied forward-looking statements included in
this press release are based on management’s current expectations
and beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward looking
statements contained in this press release, including, without
limitation those uncertainties related to the advancement of our
clinical program, the expected impact and contribution of our board
of directors and executives to our business, and other risks
identified in our SEC filings, including those set forth under the
caption “Risk Factors” in Forma’s Quarterly Report on Form 10-Q for
the quarter ended September 30, 2021, as well as other risks
detailed in our subsequent filings with the Securities and Exchange
Commission. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. Forma undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise. Any forward-looking
statements contained in this press release represent our views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date. We explicitly disclaim any
obligation to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220113005228/en/
Media: Adam Silverstein, +1 917-697-9313 Porter Novelli
adam.silverstein@porternovelli.com
Investor: Mario Corso, +1 781-366-5726 Forma Therapeutics
mcorso@formatherapeutics.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024